[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity

Rhea-AI Filing Summary

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, reported the disposition of 714 shares of the company's common stock on 09/15/2025 at a price of $25.61 per share. The sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person effective 12/11/2024. After the reported transaction, the reporting person beneficially owned 77,357 shares, held directly. The Form 4 was signed and filed on 09/17/2025, and the filing indicates it was submitted by one reporting person.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating the trade was pre-planned and compliant with insider trading rules
• Clear, timely disclosure of transaction date, price, and resulting beneficial ownership on Form 4

Negative

• Reduction in insider holdings by 714 shares following the sale

Insights

Financial Analyst

TL;DR: A routine officer sale of 714 shares under a pre-established 10b5-1 plan; modest change to insider holdings.

The transaction is a disclosed, non-derivative sale executed through a Rule 10b5-1 plan, which generally indicates pre-planned dispositions rather than opportunistic trades. The size of the sale (714 shares at $25.61) is small relative to the remaining direct holding of 77,357 shares, so the immediate impact on share supply or valuation is likely negligible. This filing provides clear, timely disclosure consistent with Section 16 reporting obligations.

Corporate Governance Expert

TL;DR: Proper disclosure and use of a 10b5-1 plan reflect governance compliance; no material red flags in the filing.

The Form 4 documents that the sale was conducted pursuant to a 10b5-1(c) plan established on 12/11/2024, which supports adherence to insider trading policies and provides an audit trail. The filing is specific about the number of shares sold, price, and resulting beneficial ownership, and it is, therefore, a transparent governance disclosure. There is no indication in the document of amendments, joint filings, or derivative activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Aebersold Sarah

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		S(1)		714	D	$25.61	77,357	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-11-2024.

Remarks:

	/s/ Sarah Aebersold	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did BLFS officer Sarah Aebersold report?

The report discloses a sale of 714 shares of BioLife Solutions (BLFS) common stock on 09/15/2025 at $25.61 per share.

Was the BLFS insider sale part of a trading plan?

Yes. The sale was effected pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective 12/11/2024.

How many BLFS shares does Sarah Aebersold beneficially own after the sale?

Following the reported transaction, the reporting person beneficially owned 77,357 shares, held directly.

When was the Form 4 for the BLFS transaction filed and signed?

The Form 4 was signed by Sarah Aebersold on 09/17/2025 and filed in connection with the 09/15/2025 transaction.

Did the Form 4 report any derivative securities or other transactions?

No. The filing reports only a non-derivative sale of common stock and shows no derivative securities transactions.